You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 143 No. 4, April 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Study
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (6)
 •Contact me when this article is cited
 Related Content
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Aging/ Geriatrics
 •Dermatologic Disorders
 •Neoplasms
 •Diagnosis
 •Prognosis/ Outcomes
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Melanoma Outcomes for Medicare Patients

Association of Stage and Survival With Detection by a Dermatologist vs a Nondermatologist

Michelle L. Pennie, MD; Seaver L. Soon, MD; Jessica B. Risser, MD, MPH; Emir Veledar, PhD; Steven D. Culler, PhD; Suephy C. Chen, MD, MS

Arch Dermatol. 2007;143(4):488-494.

Objective  To determine whether a difference in melanoma outcomes exists in the United States between tumors detected by dermatologists vs those detected by nondermatologists.

Design  Retrospective analysis of linked data from the Medicare enrollment and claims files from the Centers for Medicare and Medicaid Services and the National Cancer Institute's Surveillance, Epidemiology, and End Results program database from 1991 to 1996. The registries are from 12 US sites.

Patients  A study sample comprised of 2020 subjects.

Main Outcome Measures  Tumor characteristics (Breslow thickness and histologic ulceration), stage at diagnosis, and survival and mortality rates.

Results  Tumor detection by a dermatologist vs nondermatologist was associated with an earlier stage melanoma (stage 0, stage I, and stage II vs stage III and stage IV; {chi}2 test, P<.01) and a thinner tumor (Breslow thickness, 0.86 mm vs 1.00 mm; P<.05). At all time points (6 months, 2 years, and 5 years), patients whose melanoma was detected by dermatologists had better survival rates (98%, 87%, and 74%, respectively, for those whose melanoma was detected by dermatologists vs 95%, 79%, and 69%, respectively, for nondermatologists; P<.05). Non–cancer-related mortality was similar for the 2 groups, but the patients whose tumors were detected by dermatologists had lower cancer-related mortality (13% vs 21%; P<.01) and overall mortality (29% vs 37%; P<.01). Multivariate analysis showed that age, sex, stage at diagnosis, and melanoma detection by a dermatologist were all significantly predictive of survival.

Conclusions  Earlier stage melanoma and improved survival are associated with detection by a dermatologist rather than by a nondermatologist. Increasing access to dermatologists, particularly for older patients, may represent one approach to improving melanoma-related health outcomes.


Author Affiliations: Departments of Dermatology (Drs Pennie, Soon, Risser, and Chen) and Medicine, Division of Cardiology (Dr Veledar), Emory University School of Medicine; and Rollins School of Public Health (Dr Culler), Atlanta, Ga; and Department of Health Services Research and Development and Division of Dermatology, Atlanta Veterans Affairs Medical Center, Decatur, Ga (Dr Chen). Dr Soon is now with Scripps Clinic, Division of Dermatology and Cutaneous Surgery, La Jolla, Calif.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED ARTICLES

Store-and-Forward Teledermatology in Skin Cancer Triage: Experience and Evaluation of 2009 Teleconsultations
David Moreno-Ramirez, Lara Ferrandiz, Adoracion Nieto-Garcia, Rafael Carrasco, Pedro Moreno-Alvarez, Rafael Galdeano, Esther Bidegain, Juan J. Rios-Martin, and Francisco M. Camacho
Arch Dermatol. 2007;143(4):479-483.
ABSTRACT | FULL TEXT  

Multiple Melanomas After Treatment for Hodgkin Lymphoma in a Non-Dutch p16-Leiden Mutation Carrier With 2 MC1R High-Risk Variants
Adina Figl, Ranjit K. Thirumaran, Selma Ugurel, Andreas Gast, Kari Hemminki, Rajiv Kumar, and Dirk Schadendorf
Arch Dermatol. 2007;143(4):495-499.
ABSTRACT | FULL TEXT  

Phenotypic Variation in Familial Melanoma: Consequences for Predictive DNA Testing
Wilma Bergman and Nelleke A. Gruis
Arch Dermatol. 2007;143(4):525-526.
EXTRACT | FULL TEXT  

Melanoma of the Foot and Ankle: A Case Series of an Underrecognized Entity
Hubert T. Greenway, Jr, Joy M. Twersky, Shanna B. Meads, and Benjamin F. Kelley
Arch Dermatol. 2007;143(4):543-544.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Metastasis of Uveal Melanoma Millimeter-by-Millimeter in 8033 Consecutive Eyes
Shields et al.
Arch Ophthalmol 2009;127:989-998.
ABSTRACT | FULL TEXT  

Melanoma in Middle-aged and Older Men: A Multi-institutional Survey Study of Factors Related to Tumor Thickness
Swetter et al.
Arch Dermatol 2009;145:397-404.
ABSTRACT | FULL TEXT  

Time Required for a Complete Skin Examination With and Without Dermoscopy: A Prospective, Randomized Multicenter Study
Zalaudek et al.
Arch Dermatol 2008;144:509-513.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.